Enanta Pharmaceuticals (ENTA) Cash Flow: Operating & Free Cash Flow

Enanta Pharmaceuticals Cash Flow Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Cash flow statement showing operating, investing, and financing activities for Enanta Pharmaceuticals, Inc. (ENTA) - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period ending	Sep 2025	Sep 2024	Sep 2023	Sep 2022	Sep 2021	Sep 2020	Sep 2019	Sep 2018	Sep 2017
Operating Activities
Net Income	-81.89	-116.05	-133.82	-121.76	-79.00	-36.17	46.38	71.96	17.71
Depreciation & Amortization	4.59	2.34	2.37	2.97	3.33	3.64	3.26	2.52	2.14
Deferred Income Tax	0.00	0.00	0.00	0.00	0.35	10.61	-3.14	1.86	-1.65
Stock Based Compensation	18.57	26.80	28.22	26.97	20.99	19.58	19.23	15.85	13.07
Change in Working Capital	39.91	7.13	8.02	6.79	-13.69	12.90	11.49	-61.79	21.97
Change in Accounts Receivable	-0.24	0.97	11.70	11.80	-24.30	27.82	15.89	-56.59	2.23
Change in Inventory	0.00	0.00	0.00	0.00	0.00	0.00	-6.48	-6.42	18.63
Change in Accounts Payable	-1.31	-0.41	-1.15	-4.63	3.77	-0.88	1.79	1.32	0.63
Change in Other Working Capital	41.40	6.57	-5.24	-0.37	6.84	-14.04	0.29	-0.09	0.48
Other Operating Activities	-0.44	1.02	-5.24	0.24	-1.98	-3.47	-5.80	-1.17	-0.58
Net Cash from Operating Activities	-19.27	-78.76	-103.15	-84.78	-70.00	7.09	71.42	29.22	52.65
Investing Activities
Capital Expenditures	-12.90	-17.95	-9.06	-2.13	-0.75	-1.45	-5.42	-2.98	-2.51
Acquisitions	0.00	0.00	44.52	-54.90	-37.74	0.00	86.66	0.00	0.00
Purchases of Investments	-209.63	-307.28	-373.39	-171.45	-307.35	-338.55	-549.31	-293.10	-251.37
Sales/Maturities of Investments	262.87	383.47	328.87	228.47	345.09	359.83	468.07	260.68	249.31
Other Investing Activities	0.00	0.00	-44.52	54.90	37.74	0.00	0.00	-32.42	-2.07
Net Cash from Investing Activities	40.35	58.24	-53.58	54.90	36.99	19.83	-86.66	-35.40	-4.57
Financing Activities
Debt Repayment	-26.49	-27.48	199.68	0.00	0.00	0.00	-0.09	-0.08	-0.07
Common Stock Issued	0.15	0.15	2.21	21.26	3.61	0.00	0.00	0.00	0.00
Common Stock Repurchased	-0.28	0.00	-3.76	0.00	0.00	0.00	0.00	0.00	0.00
Other Financing Activities	-26.76	-0.29	195.92	-1.23	-0.53	8.98	2.66	4.49	1.09
Net Cash from Financing Activities	-26.62	-27.63	198.13	20.03	3.08	8.98	2.57	4.41	1.02
Summary
Net Change in Cash	-5.54	-48.16	41.39	-9.85	-29.93	35.90	-12.67	-1.77	49.10
Cash at Beginning of Period	41.20	89.36	47.96	57.81	87.74	51.84	64.51	65.68	16.58
Cash at End of Period	35.66	41.20	89.36	47.96	57.81	87.74	51.84	63.90	65.68
Free Cash Flow	-32.17	-96.71	-112.21	-86.91	-70.75	5.64	66.00	26.24	50.15
Supplemental Disclosures
Interest Paid	8.79	11.71	1.99	-	-	-	-	-	-
Income Taxes Paid	-33.68	0.24	4.90	-	0.03	-	-	-	-

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Enanta Pharmaceuticals Cash Flow

What is Enanta Pharmaceuticals's free cash flow?

Enanta Pharmaceuticals had negative free cash flow of $32.17M in fiscal 2025 (fiscal year ended Sep 30, 2025), operating cash flow of −$19.27M minus $12.90M of capital expenditures.

How much does Enanta Pharmaceuticals spend on capital expenditures?

Enanta Pharmaceuticals spent $12.90M on capital expenditures in fiscal 2025, compared with $17.95M a year earlier.

Does Enanta Pharmaceuticals pay dividends or buy back shares?

Yes. In fiscal 2025 Enanta Pharmaceuticals returned $277.00K in share buybacks to shareholders, according to its cash flow statement.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition